RBC Capital Reiterates Outperform Rating on Insulet Corporation (PODD)

Market Context

Insulet Corporation operates in the Healthcare sector. The stock currently trades at $139.30 with a market capitalization of $20.7B. The stock has declined 57.4% over the past 52 weeks.

Analyst coverage from RBC Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Insulet Corporation.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Insulet Corporation

Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 06, 2026	Leerink Partners	Market Perform	N/A
Aug 06, 2026	Benchmark	Buy	N/A
Aug 06, 2026	Bernstein	Outperform	N/A
Aug 06, 2026	RBC Capital	Outperform	N/A
Aug 06, 2026	UBS	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View PODD Stock Page